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cific diagnosis and pre-visit medication use, the associa-
tion between quality of life measurements and change in
therapy was no longer significant. CONCLUSION: Pa-
tients with musculoskeletal disorders who perceive their
mental and physical health as poor and report greater
levels of functional limitations are more likely to receive
an additional medication during a medical encounter.
Since therapy change is also a function of specific patient
diagnosis, future analyses should evaluate self-rating
health scores and therapy change within patients with
specific diagnosis.
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Patient registries go beyond clinical trials with respect to
the assessment of long-term outcomes and measures of
effectiveness. OBJECTIVES: To assess the long-term
safety and effectiveness of cyclosporine (CyA) in a popu-
lation with severe RA. METHODS: All RA patients in
British Columbia treated with CyA between 1991 and
1997 were registered. Demographics and RA treatments
were prospectively collected. Joint count [JC], morning
stiffness [MS], fatigue duration and toxicity parameters
(systolic and diastolic blood pressure [SBP and DBP], and
serum creatinine [SCr]) were assessed monthly up to 84
months. Baseline and serial data were compared using
paired tests. Survival analysis was used to assess time to
CyA discontinuation. RESULTS: 133 severe RA patients
[100 (75%) female, median age 58 years (28–82), median
RA duration 13.5 years (2–54), 98% previous DMARD]
were evaluated. CyA treatment data included duration
(median 14 months, 2–84), dose changes (median 8,
3–42), and dose at cessation (mean 3.25 mg/kg/day, 1.2–
4.5). 27 (25%) received concomitant methotrexate ther-
apy. CyA discontinuation occurred in 37 (28%) patients
due to ineffectiveness (29) and toxicity (8). Significant re-
ductions occurred in JC up to 24 months (32%, 41%,
and 54% at 6, 12, and 24 months respectively; all P 
0.001), and in fatigue duration (55% and 71% at 24 and
36 months respectively; P  0.019 and 0.009). SBP,
DBP, and SCr were significantly elevated over baseline
values throughout treatment. Discontinuation followed a
bimodal pattern with most occurring between 10 and 20
months and a slower rate thereafter. CONCLUSIONS:
Longterm treatment with CyA appears to be effective for
severe RA however SBP, DBP and SCr are adversely af-
fected in most patients.
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OBJECTIVES: To determine the state-of-the-art in qual-
ity-of-life assessment associated with male sexual func-
tioning/erectile dysfunction. METHODS: Using Medline,
we identified assessment instruments and scales by search-
ing the keywords: “erectile dysfunction,” “impotence,”
“quality of life,” and “sexual dysfunction.” We focused
on scales published since 1980 in English with evidence
of validity and reliability. We then evaluated these scales
regarding their primary use, operationalization of do-
mains, and psychometric properties. RESULTS: We in-
cluded 19 instruments designed to measure aspects of
male sexual functioning. Instruments were classified by
their primary use into symptom measures (11), quality-
of-life measures (3), couple assessments (4-one of these
was also counted as a symptom measure), treatment sat-
isfaction questionnaires (1), and diagnostic tools (1).
Most measured the domains of sex drive, erection, and
orgasm, using different terms and approaches. Addition-
ally, the domains varied in how they were operational-
ized, with some instruments assessing frequency and
others measuring intensity. Psychometric data revealed
varying degrees of methodological sophistication. CON-
CLUSIONS: There are a variety of scales available for
the assessment of male sexual functioning and erectile
dysfunction. However, the development of these mea-
sures has been ad hoc, with relatively little uniformity in
terms of which domains are measured and how common
domains are operationalized. Most questionnaires are
symptom measures, which do not measure the conse-
quences of erectile dysfunction on quality of life. Conse-
quently, a new instrument to explicitly assess domains of
quality of life associated with erectile dysfunction, in ad-
dition to symptoms, would be a valued addition to the
literature in support of clinical practice and research.
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OBJECTIVE: To assess the effect of short-term testoster-
one enanthanate (T) supplementation on health-related
quality of life (HRQOL) in healthy, elderly males.
METHODS: As part of a double-blind, placebo-con-
trolled study, 22 healthy males  65 years were random-
ized to receive a total of 4 doses of T 200 mg or placebo
(P) intramuscularly every 2 weeks. HRQOL was assessed
using the SF-36 and Psychological General Well-Being
(PGWB) scales at baseline and after 8 weeks. Data was
analyzed using unpaired and paired t-tests, adjusting for
covariates. The study had 80% power to detect a 20-
point difference in 4 of the SF-36 domains and the PGWB
score; a P-value 0.05 was considered statistically signif-
icant. RESULTS: The mean age in the T (n  14) and P
(n  8) groups was 73.1  3.1 and 70.1  4.2 years, re-
spectively. Baseline PGWB scores were similar between
the groups (T:93.2,P:92.1). Baseline SF-36 scores were
similar between the groups: physical functioning (PF)
(T:93.9,P:82.5), role-physical (RP) (T:92.9,P:93.8), bodily
pain (BP) (T:86.1,P:81.6), general health (GH) (T:84.4,
P:76.9), social functioning (SF) (T:99.1,P:95.3), role-
emotional (RE) (T:90.4,P:100.0) and mental health
(MH) (T:84.7,P:76.0,); only vitality (VT) was signifi-
cantly different at baseline (T:80.4,P:65.6; P  0.007).
After 8 weeks, SF-36 scores were similar between the
groups:- PF (T:96.5,P:91.7), RP (T:92.3,P:100.0), BP
(T:91.5,P:87.2,), GH (T:87.1,P:79.2), VT (T:80.0,P:74.2),
SF (T:96.2,P:100.0), RE (T:89.7,P:100.0), MH (T:88.1,
P:90.0). PGWB scores were not significantly different be-
tween the groups (T:95.0,P:95.8) and there was no signif-
icant change within each group in HRQOL scores over
time. CONCLUSION: Healthy males  65 years have
high baseline HRQOL scores which are not enhanced by
short-term testosterone supplementation.
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The use of computerized databases to identify and follow
large cohorts of pregnant women make it feasible to
study trends in prescribing practices and to quickly iden-
tify defined cohorts of exposed pregnancies for further
research. OBJECTIVES: This study had two purposes, to
develop a methodology to identify pregnant women in an
automated database and determine the type and extent of
prescription drug use during a defined pregnancy period.
METHODS: A retrospective analysis of prescription
claims from an integrated managed care data base. The
study population consisted of women, aged 12–50 years
of age with a pregnancy indication during the period 10/
12/96–12/31/98. Pregnant women were identified using
ICD-9-CM diagnosis and procedure codes and CPT-4
codes. The pregnancy period was defined using date of
service fields. RESULTS: 4,732 women were identified
with a pregnancy during the specified time frame. 826
(17%) of these members had claims evidence of prescrip-
tion drug acquisition. Each woman received on average 2
different medications during pregnancy and an average
of 4.5 prescriptions. 25% of the prescription were agents
defined as pregnancy class C (prescription anthihistamine
agents, antiinfective agents and psychiatric medications
such as lithium and phenothiazines), 4% were defined as
pregnancy class D (antidepressant agents such as amitrip-
tyline and nortriptyline, anticonvulsant agents), and 7%
were classified as pregnancy class X (isotretinoin and es-
trogen preparations). Pregnancy class X poses the largest
concern. 115 women were identified with claims for oral
contraceptives that did not appear during the first or last
month of the pregnancy period. One woman was identi-
fied with claims for isotretinoin during the pregnancy pe-
riod. CONCLUSIONS: Information contained in the
claims data provides evidence regarding the use of pre-
scription drugs during pregnancy. Despite warnings in
literature and public media drugs defined as pregnancy
class X are acquired during the pregnancy period.
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Current trends in epidemiologic, economic and broader
effects of ED have implications for both public health
and patient QoL. Therefore evaluation of the impact of
the condition as well as new and competing treatments
must include assessment of QoL outcomes. Different
measures have been developed for assessing the impact of
ED and its treatments. Selection of one or more of these
measures for clinical research and practice must be based
on a careful comparison of published evidence of their
psychometric validity including responsiveness. OBJEC-
TIVES: To evaluate the psychometric properties and rele-
vance of measures used for assessing QoL in published
studies focusing on male sexual functioning in ill or well
subjects. METHODS: The literature search of MED-
LINE, EMBASE covered the period from 1966 to date
using various terms including QoL, satisfaction, impo-
tence and erectile dysfunction and was complemented by
a search of bibliographic data from our Information Re-
sources Center. RESULTS: 30 assessment tools have
been systematically reviewed in detail for their measure-
ment characteristics including psychometric properties.
These were made up of 19 sexuality/ED-specific mea-
sures, 3 generic multi-dimensional QoL instruments, 7
psychological scales and one satisfaction measure. We
found marked differences amongst instruments in terms
of domains covered and extent of psychometric valida-
tion of measures in the same taxonomic category. In par-
